PDF(Pubmed)
Abstract：
UNASSIGNED: Immune checkpoint inhibitors (ICIs) represent a novel class of agents approved for the treatment of several cancers and progressive multifocal leukoencephalopathy (PML). However, due to the risk of autoimmune side effects, their use in people with autoimmune diseases such as multiple sclerosis (MS) has been limited.
UNASSIGNED: To characterize outcomes in a cohort of adults with MS who received ICIs.
UNASSIGNED: A single-center retrospective review of medical record data was performed for people with MS treated with ICIs.
UNASSIGNED: Seven people with MS were identified, with a mean (SD) age at ICI use of 55.4 (13.7) years and a mean MS duration of 18.2 (12.2) years. Six were treated for cancer; 1 was treated for PML. After mean (SD) follow-up of 1.76 (2.15) years after ICI, outcomes are: no evidence of disease (2), residual metastatic disease (1), death due to cancer (1), death due to PML (1), and lost to follow-up (2). Notably, 0 out of 7 patients experienced an MS relapse; two out of six had new asymptomatic demyelinating magnetic resonance imaging lesions. In the three patients with expanded disability status scale (EDSS) scores at baseline and follow-up, EDSS remained stable (mean delta 0.13).
UNASSIGNED: In this cohort, no people with MS experienced clinical relapses and one-third experienced asymptomatic radiological activity following ICI treatment.
UNASSIGNED: To characterize outcomes in a cohort of adults with MS who received ICIs.
UNASSIGNED: A single-center retrospective review of medical record data was performed for people with MS treated with ICIs.
UNASSIGNED: Seven people with MS were identified, with a mean (SD) age at ICI use of 55.4 (13.7) years and a mean MS duration of 18.2 (12.2) years. Six were treated for cancer; 1 was treated for PML. After mean (SD) follow-up of 1.76 (2.15) years after ICI, outcomes are: no evidence of disease (2), residual metastatic disease (1), death due to cancer (1), death due to PML (1), and lost to follow-up (2). Notably, 0 out of 7 patients experienced an MS relapse; two out of six had new asymptomatic demyelinating magnetic resonance imaging lesions. In the three patients with expanded disability status scale (EDSS) scores at baseline and follow-up, EDSS remained stable (mean delta 0.13).
UNASSIGNED: In this cohort, no people with MS experienced clinical relapses and one-third experienced asymptomatic radiological activity following ICI treatment.
摘要：
■免疫检查点抑制剂（ICIs）代表一类新型药物，已被批准用于治疗几种癌症和进行性多灶性白质脑病（PML）。然而,由于自身免疫副作用的风险，它们在自身免疫性疾病如多发性硬化症（MS）患者中的使用受到限制。
■用于表征接受ICIs的MS成人队列的结局。
■对接受ICIs治疗的MS患者的病历数据进行单中心回顾性审查。
■确定了7名MS患者，ICI使用时的平均（SD）年龄为55.4（13.7）岁，平均MS持续时间为18.2（12.2）年。6例治疗癌症；1例治疗PML。在ICI后1.76（2.15）年的平均（SD）随访后，结果是：没有疾病的证据（2），残余转移性疾病（1），癌症死亡（1）因PML死亡（1），失去了后续行动（2）。值得注意的是,7例患者中有0例出现MS复发；6例中有2例出现新的无症状性脱髓鞘磁共振成像病变。3例患者在基线和随访时的扩展残疾状况量表(EDSS)评分,EDSS保持稳定(平均Δ0.13)。
■在此队列中，在ICI治疗后,MS患者没有出现临床复发,1/3出现无症状放射性活动.
■用于表征接受ICIs的MS成人队列的结局。
■对接受ICIs治疗的MS患者的病历数据进行单中心回顾性审查。
■确定了7名MS患者，ICI使用时的平均（SD）年龄为55.4（13.7）岁，平均MS持续时间为18.2（12.2）年。6例治疗癌症；1例治疗PML。在ICI后1.76（2.15）年的平均（SD）随访后，结果是：没有疾病的证据（2），残余转移性疾病（1），癌症死亡（1）因PML死亡（1），失去了后续行动（2）。值得注意的是,7例患者中有0例出现MS复发；6例中有2例出现新的无症状性脱髓鞘磁共振成像病变。3例患者在基线和随访时的扩展残疾状况量表(EDSS)评分,EDSS保持稳定(平均Δ0.13)。
■在此队列中，在ICI治疗后,MS患者没有出现临床复发,1/3出现无症状放射性活动.
